Rahul R Aggarwal
University of California, San Francisco · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rahul R Aggarwal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04471974 · ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerRahul Aggarwal · active not recruiting · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma · principal investigator
- Ph2NCT03284385 · Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2National Cancer Institute (NCI) · active not recruiting · Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A novel chemical strategy to harness the tumor specific biochemistry of human kallikrein 2 for prostate cancer theranosticsR01CA308884 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2026 · $575,178 awarded in 2026Same name and institution; not confirmed by an ID
- Maximizing tumor responses to targeted radiotherapy with a conditionally activated membrane binding probeR01CA279328 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2024 to 2026 · $598,123 awarded in 2026Same name and institution; not confirmed by an ID
- Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy MonitoringR01CA256740 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2021 to 2025 · $669,724 awarded in 2025Same name and institution; not confirmed by an ID
- Molecular imaging of novel PARP inhibitor nanomedicine deliveryR01CA266666 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2022 to 2025 · $621,383 awarded in 2025Same name and institution; not confirmed by an ID
- Precision targeting of T cell cytotoxicity with PETR01CA258297 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2021 to 2025 · $643,445 awarded in 2025Same name and institution; not confirmed by an ID
- Combining immunotherapy with molecularly targeted radiation therapyR01CA276785 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2023 · $663,343 awarded in 2023Same name and institution; not confirmed by an ID
- Targeting Neuroendocrine Prostate Cancer Using Multi-Probe Hyperpolarized 13C MRI for Improved Treatment and Therapeutic MonitoringR01CA215694 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2017 to 2021 · $655,889 awarded in 2021Same name and institution; not confirmed by an ID
- Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate CancerR01CA229354 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2019 to 2020 · $368,455 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT03284385
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:33 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.BMC Cancer · 2019174 citationsRCR 6.9
- A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.Clin Cancer Res · 2020123 citationsRCR 4.8
- Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.Clin Cancer Res · 201775 citationsRCR 1.9
- 21 citationsRCR 4.9
- High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.Clin Genitourin Cancer · 201719 citationsRCR 0.5
- A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Cancer Res Commun · 202415 citationsRCR 1.5
- Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.Br J Cancer · 202311 citationsRCR 0.9
- 10 citationsRCR 0.2
- A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).Prostate Cancer Prostatic Dis · 202510 citationsRCR 2.6
- A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.Cancer Res Commun · 20227 citationsRCR 0.5